Previous 10 | Next 10 |
Gainers: Vascular Biogenics (VBLT) +22%, Sunesis Pharmaceuticals (SNSS) +21%, Savara (SVRA) +8%, Pandion Therapeutics (PAND) +5%.Losers: PAVmed (PAVM) -17%, Isoray (ISR) -16%, Vaccinex (VCNX) -16%, Onconova Therapeutics (ONTX) -15%, elect...
Palm Beach, FL –February 23, 2021 – In the breast cancer therapy market, the rise in the prevalence of cancer, has propelled the T-cell therapy market over the last few years and it is projected to continue to do so for several years to come. T-cell therapy includes using gene...
ROCHESTER, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that Surface Oncology will be exer...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Vaccinex, Inc Surges After Announcing Two Mulit-Project Deals with Leading Pharmaceutical Companies ” Vaccinex, Inc. (NASDAQ: VCNX) skyrocke...
Gainers: Vaccinex (VCNX) +106%.Evolus (EOLS) +75%.Energous (WATT) +45%.Viomi Technology (VIOT) +44%.Casa Systems (CASA) +42%.Canaan (CAN) +40%.JMP Group (JMP) +39%.Renren (RENN) +37%.The9 (NCTY) +32%.Forest Road Acquisition (FRX) +26%.Losers: China SXT Pharmaceuticals (SXT...
Vaccinex (VCNX) has announced the signing of multi-project deals with two undisclosed prominent pharmaceutical companies.The collaborations will focus on using ActivMAb, Vaccinex’s antibody discovery and novel viral display platform, for antibody discovery against complex antigens such...
ROCHESTER, N.Y., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced the signing of multi-project deals...
ROCHESTER, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, today announced that it will participate in the 10...
Vaccinex (VCNX): Q3 GAAP EPS of -$0.44 misses by $0.01.Revenue of $0.05M (-87.5% Y/Y)Press Release For further details see: Vaccinex EPS misses by $0.01
Addition al data from SIGNAL Huntington’s disease (HD) trial support continued development in H D and in Alzheimer’s disease (AD) Phase 1/2 Study to Evaluate Pepinemab in Combination with KEYTRUDA ® in Advanced, Recu...
News, Short Squeeze, Breakout and More Instantly...
Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 06, 2024 (GLOBE NEWSWIRE) -- Vaccinex, I...
A look at the top 10 most actives in the United States Novo Integrated Sciences Inc. (NVOS) rose 132.8% to $1.05 on volume of 308,155,573 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.9% to $0.0387 on volume of 278,348,616 shares Faraday Future Intelligent Electric Inc. (FFIE) ...
Vaccinex, Inc. (NASDAQ: VCNX) is one of today's top gainers. The company's shares have moved 15.16% on the day to $6. Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet...